BioMarin Pharmaceutical’s Roctavian (valoctocogene roxaparvovec) is on track to be approved as the first gene therapy in the EU for hemophilia A, after the European Medicines Agency recommended that it be granted a conditional marketing authorization.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?